
    
      PRIMARY OBJECTIVES:

      I. To determine if 12 weeks of topical itraconazole gel reduces basal cell carcinoma (BCC)
      biomarkers (Gli1, the target gene of the Hedgehog pathway).

      SECONDARY OBJECTIVES:

      I. To determine if topical itraconazole gel will decrease BCC size.

      OUTLINE:

      Patients apply itraconazole topically twice daily (BID) and placebo topically BID for 12
      weeks.

      After completion of study treatment, patients are followed up for up to 14 weeks.
    
  